Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.	Substitute fo	r form 1449B/	/PTO		Complete if Known
	INFORMATION			Application Number	- 10 0 /6 /18
	STATEMEN'	<b>FBY APPLI</b>	CANT	Filing Date	09/30/2003
	Date Submitte	d: October	1 2003	First Named Inventor	Kohel Nishikawa et al.
				Group Art Unit	- WY TARK
i i	(use as many s	heets as ne	cessary)	Examiner Name	SPIVALA
Sheet	1	of	5	Attorney Docket Number	087147-0489

		U.S. Patent	S. Patent Document		Date of Publication of	Pages, Columns, Lines, Where Relevant
Examiner Initials*	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
PS	A1	5,128,356	A	Naka et al.	07-07-1992	
<del>- [}-</del>	A2	5,162,326	A	Naka et al.	11-10-1992	
	A3	5,183,899	A	Naka et al.	02-02-1993	
	A4	5,196,444	A	Naka et al.	03-23-1993	
	A5	5,250,554	A	Naka et al.	10-05-1993	
	A6	5,284,661	Â	Morimoto et al.	02-08-1994	
	A7	5,719,173	À	Nishikawa et al.	02-17-1998	
	A8	5,889,036	A	Nishikawa et al.	03-30-1999	
	A9	6,319,938	B	Nishikawa et al.	11-20-2001	
,						

					DEICH PATENT DOCUMENT	re		
Examiner Initials*	Cite No.1	Fr. Office	oreign Patent D		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ <sup>6</sup>
1)=	Ã10	EP	0 392 317	A2	THOMAE GMBH DR K	10-17-1990		<del> </del>
-V>	A11	ĒΡ	0 400 835	A1	MERCK & CO. INC.	12-05-1990		<del> </del>
1	A12	EP	0 430 300	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	06-05-1991		ļ .
	A13	EP	0 434 038	A1	TAKEDA CHEMICAL INDUSTRIES, LTD.	06-26-1991		
	A14	EP	0 425 921	A1	TAKEDA CHEMICAL INDUSTRIES, LTD.	05-08-1991		ļ
	A15	EP	0 445 811	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	09-11-1991		
1	A16	EP	0 461 039	A1	ROUSSEL UCLAF	11-12-1991		+
	A17	ĒΡ	0 591 136	A1	BOEHRINGER INGELHEIM KG (DE); RITZAU PARI WERK GMBH PAUL	03-07-1991		
	A18	EP	0 483 683	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	05-06-1992	·	-
	A19	EP	0 518 033	A1	TAKEDA CHEMICAL INDUSTRIES, LTD.	12-16-1992		
	A20	EP	0 520 423	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	12-30-1992		
	A21	EP	0 588 299	A2	INDUSTRIES, LTD.	03-23-1994		-
1	A22	EP	0 603 712	A2		06-29-1994		

		——————————————————————————————————————	
Examiner	phullis Spivack	Date Considered	7/10/05
Signature	P IM III 3 S IVV WOIT		and the state of t

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number. Substitute for form 1449B/PTO				PTO	Complete if Known			
	INFORMATI				Application Number	Unassigned		
					Filing Date	09/30/2003		
STATEMENT BY APPLICANT  Date Submitted: October 1, 2003					First Named Inventor	Kohei Nishikawa et al.		
	Date Submitt	ed: Octob	ber 1	, 2003	Group Art Unit	Unassigned		
(use as many sheets as necessary)				cessary)	Examiner Name	Unassigned		
Sheet	2		of	5	Attorney Docket Number	087147-0489		

				FC	REIGN PATENT DOCUMEN	13		<del>,                                    </del>
Examiner Initials*	Cite No.1	Office	oreign Patent D Number <sup>4</sup>		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	  -
Δ	A23	wo	92/00067	A2	DU PONT	01-09-1992		—
15	A24	wo	92/04343	A1	YAMANOUCHI PHARMA CO., LTD.	03-19-1992		_
1	A25	wo	92/10182	A1	SMITHKLINE BEECHAM PLC	06-25-1992		_
								上
								+
								1
			· ·					上
		├	<del> </del>	<del>-</del>				
	<u> </u>	<u> </u>	<b></b>		ļ			1

			NON PATENT LITERATURE DOCUMENTS	
	Examiner Initials*		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ <sup>6</sup>
1	75	A26	CATTELL, "Macrophages in acute glomerular inflammation," <u>Kidney Int.</u> , 1994, pp. 945-952, Vol. 45, © International Society of Nephrology, London, England	
		A27	EL NAHAS, "Growth factors and glomerular sclerosis," <u>Kidney Int.</u> , 1992, pp. S15-S20, Vol. 41, Suppl. 36© International Society of Nephrology, Sheffield, United Kingdom.	
		A28	OKUDA et al., "Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis," <u>J. Clin. Invest.</u> , August 1990, pp. 453-462, Vol. 86, © The American Society for Clinical Investigation, Inc., USA	
	1	A29	COUSER, "Pathogenesis of glomerulonephritis," <u>Kidney Int.</u> , 1993, pp. S19-S26, Vol. 44, Suppl. 42, © International Society of Nephrology, Seattle, Washington, USA	
	+	A30	ZATZ et al., "Pathogenesis of Diabetic Microangiopathy, The Hemodynamic View," Am. J. Med., March 1986, pp. 443-453, Vol. 80, USA	
	+	A31	MOUSTONEN et al., "The nephrotic syndrome in IgA glomerulonephritis, response to corticosteroid therapy," Clin. Nephrol., 1983, p. 172, Vol. 20, No. 4	
	$ \sqrt{} $	A32	SATO et al., "Clinical and histological characteristics of patients with IgA nephropathy showing massive proteinuria," Jp. Nephrol., 1986, p. 1179, Vol. 28, No. 9	

		<del></del>		
Examiner Signature	Phullis Spivack	Date Considered	7/10/05	-
Signatura	The state of the seafernment with MIDED SC	o Draw line through citation if	not in conformance ar	nd not

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.30. <sup>4</sup>Applicant is to place a check mark here if <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if <sup>6</sup>Kind of document by the appropriate symbols are indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if <sup>6</sup>Kind of document under WIPO Standard ST. 16 if possible is a check mark here if <sup>6</sup>Kind of document under WIPO Standard ST. 16 if possible is a check mark here if <sup>6</sup>Kind of document under WIPO Standard ST. 16 if possible is a check mark here if <sup>6</sup>Kind of document under WIPO Standard ST. 16 if possible is a check mark here if <sup>6</sup>Kind of document under WIPO Standard ST. 16 if possible is a check mark here if <sup>6</sup>Kind of document under WIPO Standard ST. 16 if possible is a check mark here if <sup>6</sup>Kind of document under WIPO Standard ST. 16 if possible is a check mark here if <sup>6</sup>Kind of document under WIPO Standard ST. 16 if possible is a check mark here if <sup>6</sup>Kind of document under WIPO English tanguage Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control

Complete if Known Substitute for form 1449B/PTO Unassigned **Application Number** INFORMATION DISCLOSURE 09/30/2003 **Filing Date** STATEMENT BY APPLICANT Kohei Nishikawa et al. First Named Inventor Date Submitted: October 1, 2003 Unassigned **Group Art Unit** Unassigned **Examiner Name** (use as many sheets as necessary) 087147-0489 Attorney Docket Number of 3 Sheet

		NON PATENT LITERATURE DOCUMENTS	_
xaminer	Cite No.1		T⁰
D<	A33	LAI et al., "Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial," Clin, Neph., 1986, pp. 174-180, Vol. 26, No. 4,	
1	A34	BALOW et al., "Effect of treatment on the evolution of renal abnormalities in lupus nephritis," New Engl. J. Med., August 23, 1984, p. 491, Vol. 311, No. 8, USA	
$\top$	A35	BRAZY et al., "Progression of renal insufficiency; role of blood pressure," <u>Kidney Int.</u> , 1989, pp. 670-674, Vol. 35, © International Society of Nephrology, USA	
,	A36	RAIJ, "Role in hypertension in progressive glomerular injury in glomerulonephritis," <u>Hypertension</u> , 1986, pp. 30-33, Vol. 8, Suppl. I	
	A37	COPPER et al., "Nephropathy in Model Combining Genetic Hypertension with Experimental Diabetes, Enalapril Versus Hydralazine and Metoprolol Therapy," <u>Diabetes</u> , December 1990, pp. 1575-1579, Vol. 39,	
	A38	FERDER et al., "Angiotensin Converting Enzyme Inhibitors Versus Calcium Antagonists in the Treatment of Diabetic Hypertensive Patients," <u>Hypertension</u> , February 1992, pp. II-237-II-242, Vol. 19, No. 2, Supp. II, Argentina	
1	A39	Murine Mesangial Cells," Am. J. Path., January 1992, pp. 95-107, Vol. 140, No. 1, @ 74110110211010101010101010101010101010101	  -
	A40	ANDERSON et al., "Angiotensin II causes mesangial cell hypertrophy," <u>Hypertension</u> , 1993, pp. 29-35, Vol. 21,	1
1	A4	REDDI et al., "Enalapril Improves Albuminuria by Preventing Glomerular Loss of Heparan Sulfate in Diabetic Rats," <u>Biochem. Med. &amp; Met. Bio.</u> , 1991, pp. 119-131, Vol. 45, © Academic Press, Inc.	

Examiner Signature	Physics Shunger Physics Shunger Shunge	Date Considered Draw line through citation if	not in conform	mance	05 and not

\*EXAMINER: Initial if reference considered, whether or rot citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if fentless translation is contached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

umber.	Substitute for form	1449B/	PTO	Complete if Known			
	INFORMATION D			Application Number	Unassigned		
	STATEMENT BY	ADDI 1	CANT	Filing Date	09/30/2003		
				First Named Inventor	Kohei Nishikawa et al.		
	Date Submitted: Od	tober '	1, 2003	Group Art Unit	Unassigned		
	(use as many sheets		cassani	Examiner Name	Unassigned		
Sheet	(use as many sneets	of	E	Attorney Docket Number	087147-0489		

		NON PATENT LITERATURE DOCUMENTS	
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T°
PS.	A42	MORRELLet al., "Effects of Converting-Enzyme Inhibition on Barrier Function in Diabetic Glomerulopathy," <u>Diabetes, Sanuary 1990</u> , pp. 76-82, Vol. 39	
	A43	KLEIN et al., "Glomerular Proteoglycans in Diabetes, Partial Structural Characterization and Metabolism of De Novo Synthesized Heparan-35SO <sub>4</sub> and Dermatan-35SO <sub>4</sub> Proteoglycans in Streptozocin-Induced Diabetic Rats," <u>Diabetes</u> , October 1986, p. 1130, Vol. 35.	
	A44	BOHM et al., "The Angiotensin II Antagonist BIBR277 Normalized Blood Pressure and Improves," The FASEB Jnl. 7(3):A246 (1993)	
	A45	DUNN, "Prostaglandins, Angiotensin II, and Proteinuria," <u>Nephron,</u> 5:30-37 (1990)	
	A46	HONMA et al., "Renal protective effects of the angiotensin II (Ang II) receptor antagonist CV-11974 ,"  JANS 4:513 (1993)	
	A47	KOHARA et al., "Angiotensin Blockade and the Progression of Renal Damage in the Spontaenously Hypertensive Rat," <u>Hypertension</u> 21(6):975-979 (1993).	
	A48	MacKENZIE et al., <u>Journal of the American Society of Nephrology</u> 4(3):775 (abstract)	+
·	A49	Antagonist," <u>Bio. Pharm.</u> 46(2):311-318 (1993) .	
V	A50	SHIBOUTA et al., <u>Japanese Pharmacology and Therapeutics</u> , 21(5):227-235 (abstract) 1993	

-				
Examiner	Mullis Spiniack	Date Considered	7/10/	15
Signature	WIND STATE OF THE	Demu line through citation if	not in conformance	e and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number. Substi	ute for form 1449B	/PTO		Complete if Known	
			Application Number	Unassigned	
INFOR	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	09/30/2003	
_			First Named Inventor	Kohei Nishikawa et al.	
Date Su	bmitted: October	1, 2003	Group Art Unit	Unassigned	
	any sheets as ne	(vassanı)	Examiner Name	Unassigned	
Sheet 5	of	E	Attorney Docket Number	087147-0489	_

Examiner Initials*	Cite No. <sup>1</sup>	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>®</sup>
PS	A51	WOLF et al., "Glucose-Induced Hypertrophy in Cultured Proximal Tubule Cells: Enhancement by Angiotensin II (AII)," The FASEB Jnl. 5(5):A1039 (1991).	
·			

Examiner. Signature	PM lis Swack	Date Considered	7/10/	05
Signature	W MAGER BOO	Draw line through citation if	not in conforma	nce and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 6

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

087147-0489

U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
Date Submitted: October 1, 2003

(use as many sheets as necessary)

Complete if Known

Application Number
Filling Date
First Named Inventor
Group Art Unit
Examiner Name

Complete if Known

Application Number
Filling Date
First Named Inventor
Group Art Unit
Examiner Name

Sheet

Attorney Docket Number

			U.S. PATENT DOCUMENTS		Pages, Columns, Lines
	U.S. Patent	Document	Name of Potentee or Applicant of		Where Relevant
Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (#	Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear
Λ1	5 128 356		Naka et al.		
			Naka et al.		
			Naka et al.		
			Naka et al.		
			Naka et al.		
			Morimoto et al.		
				1	
			Nishikawa et al.		
			Nishikawa et al.	11-20-2001	
Wa	0,313,330				
ļ					<u> </u>
	A1 A2 A3 A4 A5 A6 A7 A8 A9	Cite No.¹  Number  A1	No.1 Number Code <sup>2</sup> (If known)  A1 5,128,356 A  A2 5,162,326 A  A3 5,183,899 A  A4 5,196,444 A  A5 5,250,554 A  A6 5,284,661 A  A7 5,719,173 A  A8 5,889,036 A	Cite No. 1         Number         Kind Code <sup>2</sup> (if known)         Name of Patentee or Applicant or Cited Document           A1         5,128,356         A         Naka et al.           A2         5,162,326         A         Naka et al.           A3         5,183,899         A         Naka et al.           A4         5,196,444         A         Naka et al.           A5         5,250,554         A         Naka et al.           A6         5,284,661         A         Morimoto et al.           A7         5,719,173         A         Nishikawa et al.           A8         5,889,036         A         Nishikawa et al.	Cite No. 1         Number         Kind Code <sup>2</sup> (if known)         Name of Patentee or Applicant or Cited Document         Cited Document MM-DD-YYYY           A1         5,128,356         A         Naka et al.         07-07-1992           A2         5,162,326         A         Naka et al.         11-10-1992           A3         5,183,899         A         Naka et al.         02-02-1993           A4         5,196,444         A         Naka et al.         03-23-1993           A5         5,250,554         A         Naka et al.         10-05-1993           A6         5,284,661         A         Morimoto et al.         02-08-1994           A7         5,719,173         A         Nishikawa et al.         03-30-1999           A8         5,889,036         A         Nishikawa et al.         11-20-2001

				FC	REIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	F: Office	oreign Patent D		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	0.10	ΕP	0 392 317	A2	THOMAE GmBH DR K	10-17-1990		
# <b>S</b>	A10	EP	0 400 835	A1	MERCK & CO. INC.	12-05-1990		
<del>-                                    </del>	A11 A12	EP	0 430 300	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	06-05-1991		
	A13	EP	0 434 038	A1	TAKEDA CHEMICAL INDUSTRIES, LTD.	06-26-1991		
	A14	EP	0 425 921	A1	TAKEDA CHEMICAL INDUSTRIES, LTD.	05-08-1991		
	A15	EP	0 445 811	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	09-11-1991		
	1.00		0 461 039	A1	ROUSSEL UCLAF	11-12-1991		-
	A16 A17	EP	0 591 136	Âİ	BOEHRINGER INGELHEIM KG (DE); RITZAU PARI WERK GMBH PAUL	03-07-1991		
	A18	EP	0 483 683	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	05-06-1992		
	A19	EP	0 518 033	A1	TAKEDA CHEMICAL INDUSTRIES, LTD.	12-16-1992		
	A20	EP	0 520 423	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	12-30-1992		
	A21	EP	0 588 299	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	03-23-1994		
	A22	EP	0 603 712	A2		06-29-1994		

				-
1	Examiner DWIII'S SWACK	Date Considered	7/10/05	<u>-</u>
	Signature   W       3		if met in conformance and not	

\*EXAMINER: Initially reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3). <sup>4</sup>For Japanese patent documents, the indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number,	Substitute f	or form 1449B	/PTO	Complete if Known		
	INFORMAT	ION DISCLO	SURE	Application Number	Unassigned	
		IT BY APPL		Filing Date	09/30/2003	
	-			First Named Inventor	Kohei Nishikawa et al.	_,-
Ĭ	Date Submit	ted: October	1, 2003	Group Art Unit	Unassigned	
	(use as many	sheets as ne	ecessary)	Examiner Name	Unassigned	
Sheet	2	of	5	Attorney Docket Number	087147-0489	

				FC	REIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	Fo Office <sup>3</sup>	oreign Patent D		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>®</sup>
PS	A23 A24 A25	wo wo	92/00067 92/04343 92/10182	A2 A1 A1	DU PONT YAMANOUCHI PHARMA CO., LTD. SMITHKLINE BEECHAM PLC	01-09-1992 03-19-1992 06-25-1992		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
P5	A26	CATTELL, "Macrophages in acute glomerular inflammation," <u>Kidney Int.</u> , 1994, pp. 945-952, Vol. 45, © International Society of Nephrology, London, England	
1	A27	EL NAHAS, "Growth factors and glomerular sclerosis," <u>Kidney Int.</u> , 1992, pp. S15-S20, Vol. 41, Suppl. 36© International Society of Nephrology, Sheffield, United Kingdom.	
	A28	OKUDA et al., "Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis," <u>J. Clin. Invest.</u> , August 1990, pp. 453-462, Vol. 86, © The American Society for Clinical Investigation, Inc., USA	
	A29	COUSER, "Pathogenesis of glomerulonephritis," <u>Kidney Int.</u> , 1993, pp. S19-S26, Vol. 44, Suppl. 42, © International Society of Nephrology, Seattle, Washington, USA	
1	A30	ZATZ et al., "Pathogenesis of Diabetic Microangiopathy, The Hemodynamic View," <u>Am. J. Med., March</u> 1986, pp. 443-453, Vol. 80, USA .	
	A31	MOUSTONEN et al., "The nephrotic syndrome in IgA glomerulonephritis, response to corticosteroid therapy," Clin. Nephrol., 1983, p. 172, Vol. 20, No. 4	
4	A32	SATO et al., "Clinical and histological characteristics of patients with IgA nephropathy showing massive proteinuria," Jp. Nephrol., 1986, p. 1179, Vol. 28, No. 9	
	1		

Examiner Signature	Phyllis Spivack	Date Considered	7/10/05
Signature	10011/3		ti al andresses and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3). <sup>6</sup>For Japanese patent documents, the indicated on the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

imber.	or form 1449B/PTO	Complete if Known		
		Application Number	Unassigned	
INFORMAT	ON DISCLOSURE	Filing Date	09/30/2003	
STATEMEN	IT BY APPLICANT	First Named Inventor	Kohei Nishikawa et al.	
Date Submit	ed: October 1, 2003	Group Art Unit	Unassigned	
		Examiner Name	Unassigned	
(use as many	sheets as necessary)		087147-0489	
Sheet 3	of 5	Attorney Docket Number	0011110101	

		NON PATENT LITERATURE DOCUMENTS	_
xaminer	Cite No.  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the articl		Τ <sup>6</sup>
0<	A33	LAI et al., "Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial," Clin Neph., 1986, pp. 174-180, Vol. 26, No. 4,	
17	A34	BALOW et al., "Effect of treatment on the evolution of renal abnormalities in lupus nephritis," New Engl. J. Med., August 23, 1984, p. 491, Vol. 311, No. 8, USA	
	A35	BRAZY et al., "Progression of renal insufficiency; role of blood pressure," <u>Kidney Int.</u> , 1989, pp. 670-674, Vol. 35, © International Society of Nephrology, USA	
,	A36	RAIJ, "Role in hypertension in progressive glomerular injury in glomerulonephritis," <u>Hypertension</u> , 1986, pp. 30-33, Vol. 8, Suppl. I	
	A37	COPPER et al., "Nephropathy in Model Combining Genetic Hypertension with Experimental Diabetes, Enalapril Versus Hydralazine and Metoprolol Therapy," <u>Diabetes</u> , December 1990, pp. 1575-1579, Vol. 39.	
	A38	FERDER et al., "Angiotensin Converting Enzyme Inhibitors Versus Calcium Antagonists in the Treatment of Diabetic Hypertensive Patients," <u>Hypertension</u> , February 1992, pp. II-237-II-242, Vol. 19, No. 2, Supp. II, Argentina	
	A39	Murine Mesangial Cells," <u>Am. J. Path.</u> , January 1992, pp. 95-107, Vol. 140, No. 1, Salitencary to of Pathologists, USA.	
	A40	ANDERSON et al., "Angiotensin II causes mesangial cell hypertrophy," <u>Hypertension</u> , 1993, pp. 29-35, Vol. 21,	
1	A41	REDDI et al., "Enalapril Improves Albuminuria by Preventing Glomerular Loss of Heparan Sulfate in Diabetic Rats," <u>Biochem. Med. &amp; Met. Bio.</u> , 1991, pp. 119-131, Vol. 45, © Academic Press, Inc.	

Examiner Signature	Date Considered  Date Considered  Date Considered	7/10/05 not in conformance and not

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Complete if Known Substitute for form 1449B/PTO **Application Number** Unassigned INFORMATION DISCLOSURE 09/30/2003 Filing Date STATEMENT BY APPLICANT Kohei Nishikawa et al. First Named Inventor Date Submitted: October 1, 2003 Unassigned Group Art Unit Unassigned **Examiner Name** (use as many sheets as necessary) 087147-0489 **Attorney Docket Number** of Sheet

		NON PATENT LITERATURE DOCUMENTS						
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						
PS,	A42	MORRELL et al., "Effects of Converting-Enzyme Inhibition on Barrier Function in Diabetic Glomerulopathy," <u>Diabetes, Danuary</u> 1990, pp. 76-82, Vol. 39						
	A43	KLEIN et al., "Glomerular Proteoglycans in Diabetes, Partial Structural Characterization and Metabolism of De Novo Synthesized Heparan- <sup>35</sup> SO <sub>4</sub> and Dermatan- <sup>35</sup> SO <sub>4</sub> Proteoglycans in Streptozocin-Induced Diabetic Rats," <u>Diabetes</u> , October 1986, p. 1130, Vol. 35.						
	A44	BOHM et al., "The Angiotensin II Antagonist BIBR277 Normalized Blood Pressure and Improves," <u>The FASEB Jnl.</u> 7(3):A246 (1993)						
	A45	DUNN, "Prostaglandins, Angiotensin II, and Proteinuria," <u>Nephron,</u> 5:30-37 (1990)						
	A46	HONMA et al., "Renal protective effects of the angiotensin II (Ang II) receptor antagonist CV-11974 ,"  JANS 4:513 (1993)	-					
	A47	KOHARA et al., "Angiotensin Blockade and the Progression of Renal Damage in the Spontaenously Hypertensive Rat," <u>Hypertension</u> 21(6):975-979 (1993).						
	A48	MacKENZIE et al., Journal of the American Society of Nephrology 4(3):775 (abstract)						
	A49	NODA et al., "Inhibition of Rabbit Aortic Angiotensin II (All) Receptor by CV-11974, A New Nonpeptide All Antagonist," Bio. Pharm. 46(2):311-318 (1993)						
1	A50	SHIBOUTA et al., <u>Japanese Pharmacology and Therapeutics</u> , 21(5):227-235 (abstract) 1993,	+					

	•			
Examiner Signature	Mullis Spinack	Date Considered  Oraw line through citation If	7/10/	15 e and not

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3). <sup>4</sup>For Japanese patent documents, the indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible is <sup>6</sup>Applicant is to place a check mark here if <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible is <sup>6</sup>Applicant is to place a check mark here if <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible is <sup>6</sup>Applicant is to place a check mark here if <sup>6</sup>Applicant is a probability in the propriate symbols as indicated on the document under WIPO Standard ST. 18 if possible is <sup>6</sup>Applicant is to place a check mark here if <sup>6</sup>Applicant is a probability in the possible is <sup>6</sup>Applicant in the possible is <sup>6</sup>Appli

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form	1449B/	PTO	Complete if Known		
			Application Number	Unassigned	
INFORMATION DI	SOLO	CANT		09/30/2003	
1				Kohei Nishikawa et al.	
Date Submitted: Oc	tober '	1, 2003		Unassigned	
		cassan/l		Unassigned	
(use as many sneets				087147-0489	
	INFORMATION DI STATEMENT BY Date Submitted: Oc	INFORMATION DISCLO STATEMENT BY APPLI Date Submitted: October (use as many sheets as ne	Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: October 1, 2003 (use as many sheets as necessary)	INFORMATION DISCLOSURE STATEMENT BY APPLICANT  Date Submitted: October 1, 2003  (use as many sheets as necessary)  (use as many sheets as necessary)  Application Number  Filing Date  First Named Inventor  Group Art Unit  Examiner Name	

		NON PATENT LITERATURE DOCUMENTS	_			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				
75	A51	WOLF et al., "Glucose-Induced Hypertrophy in Cultured Proximal Tubule Cells: Enhancement by Angiotensin II (All)," The FASEB Jnl. 5(5):A1039 (1991).				

	0			
Examiner Signature	PM Vis	Spirack	Date Considered	7/10/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.